Gene Therapy Development Service for T1DM

Gene Therapy Development Service for T1DM

T1DM is a chronic disease in which the immune system attacks and destroys the β-cells, leading to high blood sugar levels. It is currently considered to be the result of the complex interaction between environmental factors and the microbiome, genome, metabolism and immune system. Ace Therapeutics can provide researchers engaged in gene therapy of diabetes with more efficient gene function analysis and overall gene therapy services.

Genetics of T1DM

The highly polymorphic HLA region on chromosome 6p21 encodes for glycoproteins belonging to the major histocompatibility complex (MHC). These molecules interact with peptide antigens, allowing the immune cells to recognize foreign antigens and trigger an immune response. Two HLA class II haplotypes involved in antigen presentation is HLA-DR and HLA-DQ.

Gene Therapy for Diabetes

The research on gene therapy for diabetes is mainly aimed at T1DM, T2DM and diabetes complications. Through the research on relevant target genes and targets and the carrier of gene targeted therapy for diabetes, a series of research and exploration have been carried out.

In T1DM, insulin secreting β-cells are destroyed by inflammatory cells, so gene therapy for T1DM is based on β-cells were the best target. At present, the methods of target gene transfer used in gene therapy can be divided into two categories.

Viral Method RNA and DNA viruses can be used as vectors for gene transfer, usually retroviral vectors and adenoviral vectors.
Non-viral Method Non-viral methods include calcium phosphate precipitation, liposome transfection and microinjection.

Immunological Barriers to Successful Recombinant Adeno-associated Virus (rAA) Gene DeliveryImmunological Barriers to Successful Recombinant Adeno-associated Virus (rAA) Gene Delivery (Wang, D.; et al. Nature reviews Drug discovery, 2019.)

Our Services

Gene therapy research provides more options for diabetes treatment. With the goal of scientific research of diabetes, Ace Therapeutics can provide a full set of services of gene therapy schemes.

Gene Therapy Cargo Development

Gene Therapy Cargo Development

  • Gene Editing (CRISPR/Cas9, TALEN, etc.)
  • mRNA
  • RNAi (siRNA, shRNA, etc.)

Gene Therapy Vector Development

Gene Therapy Vector Development

  • Viral Vector: AAV, Lentivirus
  • Non-viral Vector: Nanoparticles, Liposomes

Features of Our Services

Highly CustomizableHighly Customizable

One-stop ServicesOne-stop Services

High QualityHigh Quality

Professional TeamProfessional Team

Ace Therapeutics offers cost-effect and high-quality research services related to T1DM gene therapy for our clients worldwide. Our assays are developed and processed with the highest standard and the results are delivered on time without compromising quality. Please feel free to contact us.


  1. Wang, D.; et al. Adeno-associated virus vector as a platform for gene therapy delivery. Nature reviews Drug discovery. 2019, 18(5), 358-378.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Related Services
Related Products
Contact Info
Copyright © Ace Therapeutics. All Rights Reserved.